A new paradigm for testing AD drugs - neuroimaging biomarkers as surrogate outcomes homologous in animals and humans

Research output: Contribution to journalArticle

Abstract

The pathological process of Alzheimer's disease (AD) starts years before the appearance of clinical symptoms. The understanding of those mechanisms at the basis of such long phase will permit the development of new drugs to counter neurodegeneration before irreversible neuronal losses occur. Ideally, the development of such drugs should be based on the markers of disease progression homologous in humans and animals. The perfect experimental model recapitulating the main pathological characteristics of AD has yet to be engineered, but available models address a number of pathological AD features allowing to translate human markers to mice. The present paper is an overview of the neuroimaging markers used to map AD-like pathology and its progression in vivo in mice models of amyloidosis. Mice models are widely used to test AD candidate drugs and to predict their effects in human. Therefore, the crucial key is the identification of AD progression imaging markers homologous to those validated in early AD patients.

Original languageEnglish
JournalDrug Discovery Today: Therapeutic Strategies
DOIs
Publication statusAccepted/In press - 2013

Fingerprint

Neuroimaging
Alzheimer Disease
Biomarkers
Pharmaceutical Preparations
Disease Progression
Amyloidosis
Pathologic Processes
Theoretical Models
Pathology

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Molecular Medicine

Cite this

@article{600ecfeb2a3e43a391e5eecfea139266,
title = "A new paradigm for testing AD drugs - neuroimaging biomarkers as surrogate outcomes homologous in animals and humans",
abstract = "The pathological process of Alzheimer's disease (AD) starts years before the appearance of clinical symptoms. The understanding of those mechanisms at the basis of such long phase will permit the development of new drugs to counter neurodegeneration before irreversible neuronal losses occur. Ideally, the development of such drugs should be based on the markers of disease progression homologous in humans and animals. The perfect experimental model recapitulating the main pathological characteristics of AD has yet to be engineered, but available models address a number of pathological AD features allowing to translate human markers to mice. The present paper is an overview of the neuroimaging markers used to map AD-like pathology and its progression in vivo in mice models of amyloidosis. Mice models are widely used to test AD candidate drugs and to predict their effects in human. Therefore, the crucial key is the identification of AD progression imaging markers homologous to those validated in early AD patients.",
author = "Moira Marizzoni and Gianluigi Forloni and Frisoni, {Giovanni B.}",
year = "2013",
doi = "10.1016/j.ddstr.2013.09.003",
language = "English",
journal = "Drug Discovery Today: Therapeutic Strategies",
issn = "1740-6773",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - A new paradigm for testing AD drugs - neuroimaging biomarkers as surrogate outcomes homologous in animals and humans

AU - Marizzoni, Moira

AU - Forloni, Gianluigi

AU - Frisoni, Giovanni B.

PY - 2013

Y1 - 2013

N2 - The pathological process of Alzheimer's disease (AD) starts years before the appearance of clinical symptoms. The understanding of those mechanisms at the basis of such long phase will permit the development of new drugs to counter neurodegeneration before irreversible neuronal losses occur. Ideally, the development of such drugs should be based on the markers of disease progression homologous in humans and animals. The perfect experimental model recapitulating the main pathological characteristics of AD has yet to be engineered, but available models address a number of pathological AD features allowing to translate human markers to mice. The present paper is an overview of the neuroimaging markers used to map AD-like pathology and its progression in vivo in mice models of amyloidosis. Mice models are widely used to test AD candidate drugs and to predict their effects in human. Therefore, the crucial key is the identification of AD progression imaging markers homologous to those validated in early AD patients.

AB - The pathological process of Alzheimer's disease (AD) starts years before the appearance of clinical symptoms. The understanding of those mechanisms at the basis of such long phase will permit the development of new drugs to counter neurodegeneration before irreversible neuronal losses occur. Ideally, the development of such drugs should be based on the markers of disease progression homologous in humans and animals. The perfect experimental model recapitulating the main pathological characteristics of AD has yet to be engineered, but available models address a number of pathological AD features allowing to translate human markers to mice. The present paper is an overview of the neuroimaging markers used to map AD-like pathology and its progression in vivo in mice models of amyloidosis. Mice models are widely used to test AD candidate drugs and to predict their effects in human. Therefore, the crucial key is the identification of AD progression imaging markers homologous to those validated in early AD patients.

UR - http://www.scopus.com/inward/record.url?scp=84889022863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889022863&partnerID=8YFLogxK

U2 - 10.1016/j.ddstr.2013.09.003

DO - 10.1016/j.ddstr.2013.09.003

M3 - Article

AN - SCOPUS:84889022863

JO - Drug Discovery Today: Therapeutic Strategies

JF - Drug Discovery Today: Therapeutic Strategies

SN - 1740-6773

ER -